

Neothetics Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 04-Apr-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 14

[Return to Table of Contents](#)

Neothetics Inc

COMPANY OVERVIEW

Company Name	Neothetics Inc
Parent Company Name	Neothetics Inc
Website	http://www.lithera.com/
Country	US
Number of Drugs in Active Development	1
Number of Inactive Drugs	0
Number of Patents as Owner	6
Number of Patents as Third Party	0
Number of Deals	1
Key Indications	Exophthalmos, Obesity, Thyroid associated ophthalmopathy, Anesthesia
Key Target-based Actions	Beta adrenoceptor agonist, Beta 2 adrenoceptor agonist, Glucocorticoid agonist, Histamine receptor antagonist
Key Technologies	Drug combination, Steroid, Ophthalmic formulation, Parenteral formulation unspecified, Small molecule therapeutic, Injectable formulation, Subcutaneous formulation, Formulation preservation, Freeze drying

COMPANY PROFILE

SUMMARY

Neothetics Inc (formerly Lithera Inc) is focused on the development of products to improve patients' aesthetics and their quality-of-life.

FINANCIAL

By December 2014, the company had completed private equity series C and D rounds to raise approximately \$14 million.

In November 2014, the company announced its initial public offering of 4,650,000 shares of its common stock at a public offering price of \$14.00 per share and also granted a 30-day option to the underwriters to purchase up to an additional 697,500 shares of common stock at the same price to cover over-allotments. At that time, the shares were scheduled to begin trading on the NASDAQ Global Market on November 20, 2014 under the ticker symbol "NEOT" and the offering was expected to close on November 25, 2014, subject to customary closing conditions. In December 2014, the offering was closed and the company planned to raise net proceeds of approximately \$60.5 million from the offering.

In December 2012, Lithera raised \$20.6 million in preferred stock equity financing. At that time, additional investments were expected to bring the total raised up to \$35.6 million. In July 2013, Lithera completed a second closing of the series C preferred stock equity financing, and secured an additional \$6.7 million, bringing the total capital raised to \$27.3 million. In February 2014, Lithera completed the final closing of the series C preferred stock equity financing, securing an additional \$8 million, bringing the total capital raised to \$35.6 million.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	8.13
Change (USD)	-0.02 (-0.25%)
Previous Close Price (USD)	8.15

[Return to Table of Contents](#)



Volume	22,407
52-Week High (USD)	14.10
52-Week Low (USD)	6.11
Date	02-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	13,868,032
Current Market Capitalization	106,090,445
EPS (Date Reported)	-2.56528

STOCK PERFORMANCE

Stock Performance




MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Mahaffey (George W)	Individual Investor	United States	197,721	1.45	1,000	0.01	19-Mar-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	26,680	0.2	0	0	28-Feb-2015

[Return to Table of Contents](#)

Dreyfus Select Managers Small Cap Growth Fund	Mutual Fund	United States	21,991	0.16	-3,430	-0.13	31-Jan-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	15,400	0.11	0	0	28-Feb-2015
Vanguard Institutional Total Stock Market Index Fund	Mutual Fund	United States	3,040	0.02	0	0	28-Feb-2015
Vanguard Balanced Index Fund	Mutual Fund	United States	1,080	0.01	0	0	31-Jan-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	730	0.01	0	0	31-Jan-2015
Vanguard Russell 2000 Index Fund	Mutual Fund	United States	720	0.01	0	0	28-Feb-2015
Vanguard Russell 2000 Growth Index Fund	Mutual Fund	United States	600	0	0	0	28-Feb-2015
Vanguard Russell 3000 Index Fund	Mutual Fund	United States	80	0	0	0	28-Feb-2015

FINANCIAL PERFORMANCE



[Return to Table of Contents](#)

	2012	2013			
Sales (USD M)	0.1	0			
Operating Income (USD M)	-5.74104	-14.422686			
Net Income (USD M)	-7.827616	-15.016253			

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-1.8655	-4.040862
2013 Q4	0	-2.537798	-2.790897
2013 Q3	0	-1.98191	-2.191651

BALANCE SHEET

Assets (USD M)

	2012	2013			
Cash & Short Term Investments	11.099858	4.364007			
Inventories - Total	0	0			
Current Assets - Total	12.584808	4.50587			
Property, Plant And Equipment - Net	0.197419	0.024401			
Other Assets - Total	0	0			
Total Assets	12.822227	4.530271			

Liabilities (USD M)

	2012	2013			
Accounts Payable	0.700218	0.643612			
Short Term Debt & Current Portion Of Long Term Debt	0.628141	0.207097			
Current Liabilities - Total	1.908678	1.528231			
Long Term Debt	0	0			
Deferred Taxes	0	0			
Other Liabilities	1.617224	2.204749			
Total Liabilities	3.525902	3.73298			

[Return to Table of Contents](#)



Stockholders Equity (USD M)

	2012	2013			
Minority Interest	0	0			
Preferred Stock	51.051921	57.488653			
Common Stock	0.000312	0.000312			
Treasury Stock	0	0			
Total Liabilities & Shareholders' Equity	12.822227	4.530271			

FORECASTS

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-3.03	-3.67	-3.03
31-Dec-2016	-1.76	-2.77	-1.76
31-Dec-2017	-1.17	-2.6	-1.17

Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0		-50.9	0
31-Dec-2016	0		-47.43	297.35
31-Dec-2017	0		-58.73	9.53

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Commercialization License	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Nutritional disorder	0	1
Ocular disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	0	5

[Return to Table of Contents](#)

Phase 1	0	1
---------	---	---

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Ocular disease	5	0	5
Neurological disease	2	0	2
Nutritional disorder	4	0	4
Dermatological disease	1	0	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

salmeterol xinafoate + fluticasone propionate (injectable, exophthalmos), Neothetics/NovaMedica

Drug Name	salmeterol xinafoate + fluticasone propionate (injectable, exophthalmos), Neothetics/NovaMedica
Key Synonyms	
Originator Company	Neothetics Inc
Active Companies	NovaMedica, Neothetics Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	Exophthalmos
Target-based Actions	Beta adrenoceptor agonist
Other Actions	Steroidal anti-inflammatory, Lipid metabolism stimulator, Corticosteroid agonist, Ophthalmological agent
Technologies	Drug combination, Ophthalmic formulation, Small molecule therapeutic, Parenteral formulation unspecified, Steroid
Last Change Date	11-Nov-2014

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

